<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39072815</PMID><DateCompleted><Year>2024</Year><Month>07</Month><Day>29</Day></DateCompleted><DateRevised><Year>2024</Year><Month>07</Month><Day>29</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1096-9071</ISSN><JournalIssue CitedMedium="Internet"><Volume>96</Volume><Issue>8</Issue><PubDate><Year>2024</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Journal of medical virology</Title><ISOAbbreviation>J Med Virol</ISOAbbreviation></Journal><ArticleTitle>An intranasal attenuated Coxsackievirus B3 vaccine induces strong systemic and mucosal immunity against CVB3 lethal challenge.</ArticleTitle><Pagination><StartPage>e29831</StartPage><MedlinePgn>e29831</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/jmv.29831</ELocationID><Abstract><AbstractText>Coxsackievirus B3 (CVB3) triggers viral myocarditis, with no effective vaccine yet. This fecal-oral transmitted pathogen has prompted interest in mucosal immunization strategies to impede CVB3 spread. We developed a new attenuated vaccine strain, named CVB3(mu). The potential of CVB3(mu) to stimulate mucosal immune protection remains to be elucidated. This study evaluates the attenuation characteristics of CVB3(mu) via a rapid evolution cellular model and RNA sequencing. Its temperature sensitivity and safety were evaluated through in vitro and in vivo experiments. The mucosal immunity protection of CVB3(mu) was assessed via intranasal immunization in Balb/c mice. The results indicate that CVB3(mu) exhibits temperature sensitivity and forms smaller plaques. It sustains fewer genetic mutations and still possesses certain attenuated traits up to the 25th passage, in comparison to CVB3(WT). Intranasal immunization elicited a significant serum neutralizing antibodies, and a substantial sIgA response in nasal washes. In vivo trials revealed CVB3(mu) protection in adult mice and passive protection in suckling mice against lethal CVB3(WT) challenges. In conclusion, CVB3(mu), a live attenuated intranasal vaccine, provides protection involving humoral and mucosal immunity, making it a promising candidate to control CVB3 spread and infection.</AbstractText><CopyrightInformation>© 2024 Wiley Periodicals LLC.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Deng</LastName><ForeName>Huixiong</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Microbiology and Immunology, Shantou University Medical College, Shantou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Yanlei</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Microbiology and Immunology, Shantou University Medical College, Shantou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>He</LastName><ForeName>Xuanting</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Microbiology and Immunology, Shantou University Medical College, Shantou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Haoyang</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Microbiology and Immunology, Shantou University Medical College, Shantou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Shenmiao</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Microbiology and Immunology, Shantou University Medical College, Shantou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Hengyao</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Microbiology and Immunology, Shantou University Medical College, Shantou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhu</LastName><ForeName>Jiacheng</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Microbiology and Immunology, Shantou University Medical College, Shantou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gu</LastName><ForeName>Liming</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Microbiology and Immunology, Shantou University Medical College, Shantou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Rui</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Microbiology and Immunology, Shantou University Medical College, Shantou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Gefei</ForeName><Initials>G</Initials><Identifier Source="ORCID">0000-0003-3070-3586</Identifier><AffiliationInfo><Affiliation>Department of Microbiology and Immunology, Shantou University Medical College, Shantou, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><Agency>Natural Science Foundation of Guangdong Province</Agency><Country /></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Med Virol</MedlineTA><NlmUniqueID>7705876</NlmUniqueID><ISSNLinking>0146-6615</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014613">Vaccines, Attenuated</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D057134">Antibodies, Neutralizing</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014765">Viral Vaccines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007071">Immunoglobulin A, Secretory</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018928" MajorTopicYN="Y">Immunity, Mucosal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000281" MajorTopicYN="Y">Administration, Intranasal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008807" MajorTopicYN="Y">Mice, Inbred BALB C</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D029822" MajorTopicYN="Y">Enterovirus B, Human</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014613" MajorTopicYN="Y">Vaccines, Attenuated</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="Y">Antibodies, Viral</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057134" MajorTopicYN="Y">Antibodies, Neutralizing</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003384" MajorTopicYN="Y">Coxsackievirus Infections</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014765" MajorTopicYN="Y">Viral Vaccines</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007071" MajorTopicYN="N">Immunoglobulin A, Secretory</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">CVB3</Keyword><Keyword MajorTopicYN="N">attenuated</Keyword><Keyword MajorTopicYN="N">intranasal immunization</Keyword><Keyword MajorTopicYN="N">mucosal immunity</Keyword><Keyword MajorTopicYN="N">vaccine</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>6</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>4</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>7</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>7</Month><Day>29</Day><Hour>12</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>7</Month><Day>29</Day><Hour>12</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>7</Month><Day>29</Day><Hour>9</Hour><Minute>49</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39072815</ArticleId><ArticleId IdType="doi">10.1002/jmv.29831</ArticleId></ArticleIdList><ReferenceList><Title>REFERENCES</Title><Reference><Citation>Garmaroudi FS, Marchant D, Hendry R, et al. Coxsackievirus B3 replication and pathogenesis. Future Microbiol. 2015;10(4):629‐653. doi:10.2217/fmb.15.5</Citation></Reference><Reference><Citation>Han Z, Zhang Y, Huang K, et al. Two Coxsackievirus B3 outbreaks associated with hand, foot, and mouth disease in China and the evolutionary history worldwide. BMC Infect Dis. 2019;19(1):466. doi:10.1186/s12879-019-4107-z</Citation></Reference><Reference><Citation>Abedi GR, Watson JT, Nix WA, Oberste MS, Gerber SI. Enterovirus and Parechovirus Surveillance—United States, 2014‐2016. MMWR Morb Mortal Wkly Rep. 2018;67(18):515‐518. doi:10.15585/mmwr.mm6718a2</Citation></Reference><Reference><Citation>Yang Q, Yan D, Song Y, et al. Whole‐genome analysis of coxsackievirus B3 reflects its genetic diversity in China and worldwide. Virol J. 2022;19(1):69. doi:10.1186/s12985-022-01796-0</Citation></Reference><Reference><Citation>Bouin A, Nguyen Y, Wehbe M, et al. Major persistent 5' terminally deleted coxsackievirus B3 populations in human endomyocardial tissues. Emerging Infect Dis. 2016;22(8):1488‐1490. doi:10.3201/eid2208.160186</Citation></Reference><Reference><Citation>Liu P, Aitken K, Kong YY, et al. The tyrosine kinase p56lck is essential in coxsackievirus B3‐mediated heart disease. Nature Med. 2000;6(4):429‐434. doi:10.1038/74689</Citation></Reference><Reference><Citation>Lasrado N, Gangaplara A, Massilamany C, et al. Attenuated strain of CVB3 with a mutation in the CAR‐interacting region protects against both myocarditis and pancreatitis. Sci Rep. 2021;11(1):12432. doi:10.1038/s41598-021-90434-w</Citation></Reference><Reference><Citation>Yin L, Chai D, Yue Y, Dong C, Xiong S. AIM2 co‐immunization with VP1 is associated with increased memory CD8 T cells and mounts long lasting protection against Coxsackievirus B3 challenge. Front Cell Infect Microbiol. 2017;7:247. doi:10.3389/fcimb.2017.00247</Citation></Reference><Reference><Citation>Gao Y, Yue Y, Xiong S. An albumin‐binding domain peptide confers enhanced immunoprotection against viral myocarditis by CVB3 VP1 vaccine. Front Immunol. 2021;12:666594. doi:10.3389/fimmu.2021.666594</Citation></Reference><Reference><Citation>Sunagar R, Singh A, Kumar S. SARS‐CoV‐2: immunity, challenges with current vaccines, and a novel perspective on mucosal vaccines. Vaccines. 2023;11(4):849. doi:10.3390/vaccines11040849</Citation></Reference><Reference><Citation>Kehagia E, Papakyriakopoulou P, Valsami G. Advances in intranasal vaccine delivery: a promising non‐invasive route of immunization. Vaccine. 2023;41(24):3589‐3603. doi:10.1016/j.vaccine.2023.05.011</Citation></Reference><Reference><Citation>Kim DS, Nam JH. Characterization of attenuated coxsackievirus B3 strains and prospects of their application as live‐attenuated vaccines. Expert Opin Biol Ther. 2010;10(2):179‐190. doi:10.1517/14712590903379502</Citation></Reference><Reference><Citation>Zeng J, Chen X, Dai J, et al. An attenuated coxsackievirus B3 vector: a potential tool for viral tracking study and gene delivery. PLoS One. 2013;8(12):e83753. doi:10.1371/journal.pone.0083753</Citation></Reference><Reference><Citation>Yeh MTe, Smith M, Carlyle S, et al. Genetic stabilization of attenuated oral vaccines against poliovirus types 1 and 3. Nature. 2023;619:135‐142. doi:10.1038/s41586-023-06212-3</Citation></Reference><Reference><Citation>Reed LJMH. A simple method of estimating fifty‐percent endpoints. Am J Hyg. 1938;27(3):493‐497.</Citation></Reference><Reference><Citation>Pan J, Wang Q, Qi M, et al. An intranasal multivalent epitope‐based nanoparticle vaccine confers broad protection against divergent influenza viruses. ACS Nano. 2023;17(14):13474‐13487. doi:10.1021/acsnano.3c01829</Citation></Reference><Reference><Citation>Lasrado N, Arumugam R, Rasquinha MT, Sur M, Steffen D, Reddy J. Mt10‐CVB3 vaccine virus protects against CVB4 infection by inducing cross‐reactive, antigen‐specific immune responses. Microorganisms. 2021;9(11):2323. doi:10.3390/microorganisms9112323</Citation></Reference><Reference><Citation>Wu F, Fan X, Yue Y, Xiong S, Dong C. A vesicular stomatitis virus‐based mucosal vaccine promotes dendritic cell maturation and elicits preferable immune response against coxsackievirus B3 induced viral myocarditis. Vaccine. 2014;32(31):3917‐3926. doi:10.1016/j.vaccine.2014.05.052</Citation></Reference><Reference><Citation>Chai D, Yue Y, Xu W, Dong C, Xiong S. Mucosal co‐immunization with AIM2 enhances protective SIgA response and increases prophylactic efficacy of chitosan‐DNA vaccine against coxsackievirus B3‐induced myocarditis. Hum Vaccines Immunother. 2014;10(5):1284‐1294. doi:10.4161/hv.28333</Citation></Reference><Reference><Citation>Wang M, Yue Y, Dong C, Li X, Xu W, Xiong S. Mucosal immunization with high‐mobility group box 1 in chitosan enhances DNA vaccine‐induced protection against coxsackievirus B3‐induced myocarditis. Clin Vaccine Immunol. 2013;20(11):1743‐1751. doi:10.1128/CVI.00466-13</Citation></Reference><Reference><Citation>Yue Y, Xu W, Hu L, Jiang Z, Xiong S. Enhanced resistance to coxsackievirus B3‐induced myocarditis by intranasal co‐immunization of lymphotactin gene encapsulated in chitosan particle. Virology. 2009;386(2):438‐447. doi:10.1016/j.virol.2009.01.029</Citation></Reference><Reference><Citation>Knisely JM, Buyon LE, Mandt R, et al. Mucosal vaccines for SARS‐CoV‐2: scientific gaps and opportunities—workshop report. NPJ Vaccines. 2023;8(1):53. doi:10.1038/s41541-023-00654-6</Citation></Reference><Reference><Citation>Morens DM, Taubenberger JK, Fauci AS. Rethinking next‐generation vaccines for coronaviruses, influenzaviruses, and other respiratory viruses. Cell Host Microbe. 2023;31(1):146‐157. doi:10.1016/j.chom.2022.11.016</Citation></Reference><Reference><Citation>Renu S, Feliciano‐Ruiz N, Ghimire S, et al. Poly(I:C) augments inactivated influenza virus‐chitosan nanovaccine induced cell mediated immune response in pigs vaccinated intranasally. Vet Microbiol. 2020;242:108611. doi:10.1016/j.vetmic.2020.108611</Citation></Reference><Reference><Citation>Leroux‐Roels G, Maes C, Clement F, et al. Randomized phase I: safety, immunogenicity and mucosal antiviral activity in young healthy women vaccinated with HIV‐1 Gp41 P1 peptide on virosomes. PLoS One. 2013;8(2):e55438. doi:10.1371/journal.pone.0055438</Citation></Reference><Reference><Citation>Ball JP, Springer MJ, Ni Y, et al. Intranasal delivery of a bivalent norovirus vaccine formulated in an in situ gelling dry powder. PLoS One. 2017;12(5):e0177310. doi:10.1371/journal.pone.0177310</Citation></Reference><Reference><Citation>Gilbert GL, Dickson KE, Waters MJ, Kennett ML, Land SA, Sneddon M. Outbreak of enterovirus 71 infection in Victoria, Australia, with a high incidence of neurologic involvement. Pediatr Infect Dis J. 1988;7(7):484‐487. doi:10.1097/00006454-198807000-00007</Citation></Reference><Reference><Citation>Wang Y, Feng Z, Yang Y, et al. Hand, foot, and mouth disease in China: patterns of spread and transmissibility. Epidemiology. 2011;22(6):781‐792. doi:10.1097/EDE.0b013e318231d67a</Citation></Reference><Reference><Citation>Sun J, Hu X‐Y, Yu X‐F. Current understanding of human enterovirus D68. Viruses. 2019;11(6):490. doi:10.3390/v11060490</Citation></Reference><Reference><Citation>Fox H, Knowlson S, Minor PD, Macadam AJ. Genetically thermo‐stabilised, immunogenic poliovirus empty capsids; a strategy for non‐replicating vaccines. PLoS Pathog. 2017;13(1):e1006117. doi:10.1371/journal.ppat.1006117</Citation></Reference><Reference><Citation>Resik S, Mach O, Tejeda A, Galindo MA, Sutter RW. Cuba's scientific contributions to global polio eradication. MEDICC Review. 2018;20(2):40‐42.</Citation></Reference><Reference><Citation>Stern A, Yeh MT, Zinger T, et al. The evolutionary pathway to virulence of an RNA virus. Cell. 2017;169(1):35‐46.e19. doi:10.1016/j.cell.2017.03.013</Citation></Reference><Reference><Citation>Macadam AJ, Stone DM, Almond JW, Minor PD. The 5' noncoding region and virulence of poliovirus vaccine strains. TIM. 1994;2(11):449‐454. doi:10.1016/0966-842x(94)90803-6</Citation></Reference><Reference><Citation>Macadam AJ, Pollard SR, Ferguson G, et al. Genetic basis of attenuation of the Sabin type 2 vaccine strain of poliovirus in primates. Virology. 1993;192(1):18‐26. doi:10.1006/viro.1993.1003</Citation></Reference><Reference><Citation>Hazini A, Dieringer B, Pryshliak M, et al. MiR‐375‐ and miR‐1‐regulated coxsackievirus B3 has no pancreas and heart toxicity but strong antitumor efficiency in colorectal carcinomas. Hum Gene Ther. 2021;32(3‐4):216‐230. doi:10.1089/hum.2020.228</Citation></Reference><Reference><Citation>Liu H, Luo H. Development of group B Coxsackievirus as an oncolytic virus: opportunities and challenges. Viruses. 2021;13(6):1082. doi:10.3390/v13061082</Citation></Reference></ReferenceList></PubmedData></PubmedArticle>